RESPIRATORY SYNCYTIAL VIRUS

This study is checking how well the ABRYSVO RSV vaccine works when given to pregnant people to protect their babies after birth. Researchers are looking at hospital records from Argentina and Uruguay to see if vaccinated mothers had infants with fewer severe RSV infections. The g…

This study is testing the safety and immune response of two new mRNA vaccines in healthy infants. One vaccine targets both RSV and human metapneumovirus, while the other targets RSV alone. The goal is to see if these vaccines are safe and can help protect young children from thes…

This study aims to see how well a vaccine (ABRYSVO) given to pregnant women works in the real world to protect their babies from being hospitalized with severe RSV lung infections. Researchers will look at the medical records of babies under 1 year old who were hospitalized in Au…

This study is testing a new, freeze-dried mRNA vaccine designed to protect adults aged 50 and older from Respiratory Syncytial Virus (RSV). Researchers are comparing two different dose levels against a placebo to see how well the vaccine triggers an immune response and how safe i…

This is an early-stage study to test the safety and immune response of a new, freeze-dried mRNA vaccine designed to protect against Respiratory Syncytial Virus (RSV). It will involve 96 healthy adults who will receive one injection of either the vaccine or a placebo. The main goa…

This study is testing an investigational mRNA vaccine designed to protect against Respiratory Syncytial Virus (RSV). The vaccine is given to pregnant women to see if it is safe and if it helps create protective antibodies that can be passed to their babies. Researchers will monit…

This study is testing a new RSV vaccine booster shot from Moderna. It's for adults aged 60 and older who received an RSV vaccine (Arexvy or Abrysvo) at least a year ago. The main goals are to see how safe the booster is and how well it strengthens the body's defenses against RSV.